INO
Price
$1.65
Change
+$0.04 (+2.50%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
109.93M
Intraday BUY SELL Signals
RARE
Price
$24.09
Change
-$0.02 (-0.08%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
2.33B
29 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INO vs RARE

Header iconINO vs RARE Comparison
Open Charts INO vs RAREBanner chart's image
Inovio Pharmaceuticals
Price$1.65
Change+$0.04 (+2.50%)
Volume$14.7K
Capitalization109.93M
Ultragenyx Pharmaceutical
Price$24.09
Change-$0.02 (-0.08%)
Volume$100.98K
Capitalization2.33B
INO vs RARE Comparison Chart in %
View a ticker or compare two or three
VS
INO vs. RARE commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (INO: $1.60 vs. RARE: $24.11)
Brand notoriety: INO: Notable vs. RARE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 105% vs. RARE: 140%
Market capitalization -- INO: $109.93M vs. RARE: $2.33B
INO [@Biotechnology] is valued at $109.93M. RARE’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • INO’s TA Score: 5 bullish, 5 bearish.
  • RARE’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, INO is a better buy in the short-term than RARE.

Price Growth

INO (@Biotechnology) experienced а 0.00% price change this week, while RARE (@Biotechnology) price change was +6.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.45%, and the average quarterly price growth was +44.85%.

Reported Earning Dates

RARE is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.33B) has a higher market cap than INO($110M). RARE YTD gains are higher at: 4.826 vs. INO (-8.046). INO has higher annual earnings (EBITDA): -105.08M vs. RARE (-483.37M). RARE has more cash in the bank: 425M vs. INO (50.8M). INO has less debt than RARE: INO (10M) vs RARE (33.8M). RARE has higher revenues than INO: RARE (631M) vs INO (182K).
INORAREINO / RARE
Capitalization110M2.33B5%
EBITDA-105.08M-483.37M22%
Gain YTD-8.0464.826-167%
P/E RatioN/AN/A-
Revenue182K631M0%
Total Cash50.8M425M12%
Total Debt10M33.8M30%
FUNDAMENTALS RATINGS
INO vs RARE: Fundamental Ratings
INO
RARE
OUTLOOK RATING
1..100
5668
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6588
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (58) in the Medical Specialties industry is somewhat better than the same rating for RARE (94) in the Biotechnology industry. This means that INO’s stock grew somewhat faster than RARE’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RARE (100) in the Biotechnology industry. This means that INO’s stock grew similarly to RARE’s over the last 12 months.

INO's SMR Rating (100) in the Medical Specialties industry is in the same range as RARE (100) in the Biotechnology industry. This means that INO’s stock grew similarly to RARE’s over the last 12 months.

INO's Price Growth Rating (65) in the Medical Specialties industry is in the same range as RARE (88) in the Biotechnology industry. This means that INO’s stock grew similarly to RARE’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as RARE (100) in the Biotechnology industry. This means that INO’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INORARE
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 13 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
INO
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CHCCX13.790.05
+0.36%
AB Discovery Growth C
NOSIX69.32-0.14
-0.20%
Northern Stock Index
SMVIX23.55-0.07
-0.30%
SEI Small Cap Value I (SIMT)
SHXPX15.96-0.07
-0.44%
American Beacon Shapiro Equity Opps Inv
PEQYX20.11-0.12
-0.59%
Putnam Focused International Equity Y

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+3.90%
AXON - INO
53%
Loosely correlated
+1.55%
ARRY - INO
52%
Loosely correlated
-0.10%
RPTX - INO
48%
Loosely correlated
+0.58%
RARE - INO
44%
Loosely correlated
-1.07%
ALNY - INO
42%
Loosely correlated
-0.26%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-1.07%
MREO - RARE
84%
Closely correlated
+16.34%
VCYT - RARE
46%
Loosely correlated
-0.92%
INO - RARE
44%
Loosely correlated
+3.90%
MLTX - RARE
37%
Loosely correlated
-5.47%
AMRN - RARE
36%
Loosely correlated
-2.57%
More